Business Context and Reporting Period
This Form 8-K, filed on May 27, 2022, reports that Mana Capital Acquisition Corp. (a Special Purpose Acquisition Company) entered into a definitive Merger Agreement with Cardio Diagnostics, Inc. Upon closing, Mana Capital will change its name to Cardio Diagnostics Holdings, Inc. The transaction is expected to close in the third or fourth quarter of 2022, with an outside closing date of December 23, 2022.
Key Financial Metrics and Transaction Terms
The filing details the financial structure of the proposed business combination rather than historical operating results.
- Base Valuation: The base value for the transaction is set at $75,000,000.
- Consideration Formula: The Aggregate Closing Merger Consideration Value is calculated by adding the aggregate exercise price of outstanding Cardio options and warrants and the amount by which Cardio's closing cash exceeds $500,000 to the base value, then subtracting the amount by which Cardio's closing net debt exceeds $500,000.
- Share Price Assumption: The calculation assumes a value of $10.00 per share of Mana Capital Common Stock.
- PIPE Investment: The parties agreed to cooperate to consummate a Private Investment in Public Equity (PIPE) of at least $3,000,000.
- Break-up Fee: Cardio has agreed to pay a break-up fee of $3,000,000 to Mana Capital under specific termination scenarios.
- Net Tangible Assets: A closing condition requires Mana Capital to hold net tangible assets of at least $5,000,001 after redemptions.
Material Changes and Transaction Mechanics
The primary material change is the entry into the Merger Agreement, which will result in Cardio Diagnostics becoming a wholly-owned subsidiary of the combined entity. Key mechanics include:
- Exchange Ratio: Cardio shareholders will receive Mana Capital shares based on an exchange ratio derived from the Aggregate Closing Merger Consideration divided by Cardio's fully diluted capital stock.
- Earnout Provisions: Cardio shareholders may receive up to an additional 1,000,000 shares in four tranches if the stock price reaches $12.50, $15.00, $17.50, and $20.00 within four years of closing.
- Indemnification Escrow: 800,000 shares of Mana Capital common stock issuable to Cardio shareholders will be held in escrow to secure indemnification obligations for 24 to 36 months.
- Management Transition: Post-closing, the board will consist of seven directors (one designated by Mana Capital, six by Cardio). All Mana Capital executive officers will resign, replaced by Cardio's current officers.
Guidance, Risks, and Conditions
The filing outlines several conditions that must be satisfied for the transaction to close, including stockholder approval from both companies, Nasdaq listing approval, and the absence of a Material Adverse Effect. Management commentary is limited to the terms of the agreement and standard forward-looking statements.
- Risks: Risks include failure to obtain stockholder or regulatory approval, inability to list on Nasdaq, disruption of operations, and the impact of the COVID-19 pandemic.
- Lock-up Agreements: Key executives and shareholders (Restricted Parties) are subject to a six-month lock-up period post-closing.
- Extension Fees: If the SEC does not declare the Form S-4 effective in time, Cardio may advance extension fees to Mana Capital, repayable in shares at $10.00 per share upon closing.
Investor Verification Checklist
- Verify the final Aggregate Closing Merger Consideration Value once closing cash and net debt figures are confirmed.
- Confirm the outcome of the Mana Capital stockholder vote on the Business Combination Proposal and related charter amendments.
- Monitor the status of the Form S-4 registration statement and Nasdaq listing approval.
- Review the definitive proxy statement for details on the 2022 Equity Incentive Plan (reserve of up to 1,600,000 shares).
- Assess the progress of the $3,000,000 PIPE investment commitment.